Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note released on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Other research analysts also recently issued reports about the company. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. Leerink Partners set a $20.00 price target on Tenax Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Trading Up 2.2 %

Shares of TENX opened at $6.57 on Friday. The stock has a fifty day moving average of $6.44 and a two-hundred day moving average of $5.33. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.89.

Institutional Trading of Tenax Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TENX. Two Sigma Investments LP acquired a new stake in shares of Tenax Therapeutics during the 4th quarter worth $84,000. Sphera Funds Management LTD. acquired a new stake in shares of Tenax Therapeutics during the 3rd quarter worth $101,000. Geode Capital Management LLC increased its holdings in shares of Tenax Therapeutics by 32.4% during the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 5,964 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Tenax Therapeutics during the 4th quarter worth $166,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Tenax Therapeutics during the 3rd quarter worth $173,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.